Published in Proc Natl Acad Sci U S A on December 17, 2012
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (2014) 6.09
T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther (2013) 1.07
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Expression of recombinant antibodies. Front Immunol (2013) 1.06
Glioblastoma cancer stem cells: Biomarker and therapeutic advances. Neurochem Int (2014) 0.96
Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunol Res (2013) 0.94
Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res (2014) 0.92
Novel immunotherapies for hematologic malignancies. Immunol Rev (2015) 0.90
A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. Oncoimmunology (2013) 0.87
Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. Oncoimmunology (2013) 0.87
Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer (2014) 0.86
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Rev Clin Pharmacol (2013) 0.84
Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. J Immunol Methods (2013) 0.83
MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates: nanoclinic in the brain. ACS Nano (2015) 0.82
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol (2016) 0.81
Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol (2014) 0.81
Immunotherapy for malignant glioma. Surg Neurol Int (2015) 0.81
Are BiTEs the "missing link" in cancer therapy? Oncoimmunology (2015) 0.81
Antibody-based immunotherapy for malignant glioma. Semin Oncol (2014) 0.80
A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors. Sci Rep (2015) 0.78
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer. Cell Res (2016) 0.75
Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells. Oncotarget (2016) 0.75
The relationship between malignant and tumor-associated cells provides a new strategy for targeted diagnosis and therapy. Oncoimmunology (2013) 0.75
New anti-cancer chemicals Ertredin and its derivatives, regulate oxidative phosphorylation and glycolysis and suppress sphere formation in vitro and tumor growth in EGFRvIII-transformed cells. BMC Cancer (2016) 0.75
Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors. Oncoimmunology (2016) 0.75
Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies. Front Oncol (2017) 0.75
CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1(+) tumor cells, and extends the survival of tumor-bearing humanized mice. Oncotarget (2017) 0.75
Targeting Malignant Brain Tumors with Antibodies. Front Immunol (2017) 0.75
Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis. Breast Cancer Res Treat (2017) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Dose translation from animal to human studies revisited. FASEB J (2007) 15.67
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Cancer immunotherapy comes of age. Nature (2011) 12.35
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Engineered antibody fragments and the rise of single domains. Nat Biotechnol (2005) 6.96
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther (2010) 4.54
Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg (2000) 3.83
The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol (2005) 2.96
Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res (2009) 2.58
Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol (1990) 2.24
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A (2007) 1.79
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol (2005) 1.64
Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res (2011) 1.61
Safer CARS. Mol Ther (2010) 1.46
Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther (2011) 1.45
EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol (2009) 1.40
Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res (1989) 1.30
CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci (2010) 1.26
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother (2010) 1.19
Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer (2000) 1.06
Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci Transl Med (2011) 0.96
Immunosuppressive properties of anti-CD3 single-chain Fv and diabody. J Immunol Methods (2004) 0.93
Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int J Cancer (2005) 0.83
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Mesothelin: a new target for immunotherapy. Clin Cancer Res (2004) 4.30
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res (2004) 4.26
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2007) 2.99
Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs (2009) 2.90
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer (2006) 2.70
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Impact of PhD training on scholarship in a neurosurgical career. J Neurosurg (2013) 2.59
Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol (2012) 2.58
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A (2009) 2.56
Recent advances in the treatment of malignant astrocytoma. J Clin Oncol (2006) 2.55
A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol (2004) 2.39
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res (2005) 2.35
Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol (2005) 2.33
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res (2002) 2.30
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res (2002) 2.23
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery (2012) 2.19
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res (2009) 2.17
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol (2005) 2.16
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol (2003) 2.16
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol (2012) 2.15
Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria. Kidney Int (2008) 2.14
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res (2010) 2.13
Proteomic and immunologic analyses of brain tumor exosomes. FASEB J (2008) 2.11
Mesothelin expression in human lung cancer. Clin Cancer Res (2007) 2.10
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res (2005) 2.05
Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med (2005) 2.04
Type 17 CD8+ T cells display enhanced antitumor immunity. Blood (2009) 2.02
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol (2007) 2.01
2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One (2011) 2.00
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun (2007) 2.00
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2010) 1.99
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res (2006) 1.99
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res (2003) 1.92
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget (2010) 1.88
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol (2009) 1.86
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res (2003) 1.85
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol (2005) 1.85
Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol (2005) 1.84
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res (2008) 1.80
Distinct roles of segregated transmission of the septo-habenular pathway in anxiety and fear. Neuron (2013) 1.78
OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res (2009) 1.77
Podocyte injury damages other podocytes. J Am Soc Nephrol (2011) 1.75
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther (2012) 1.75
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery (2007) 1.74
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog (2007) 1.74
Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov (2004) 1.74
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood (2008) 1.74
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res (2008) 1.71
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J (2011) 1.70
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther (2009) 1.67
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther (2005) 1.66